AmplifyBio

AmplifyBio, an emerging leader among mRNA discovery, development, and manufacturing service providers, announced today that it has formalized a partnership with Stephen Burgess, Ph.D. (AvaBurg LLC), to provide expertise in LNP formulations to ensure efficient encapsulation, protection, and delivery of mRNA to cells.

AmplifyBio, a Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) focused on differentiating services that cover target optimization, preclinical safety studies, and manufacturing scale-up, and RNAV8 Bio, an emerging startup focused on mRNA engineering platforms, are partnering to provide a one-stop shop for the development of mRNA therapeutics.

J. Kelly Ganjei, CEO of AmplifyBio, recently participated in a fireside chat panel at Advanced Therapies Week, a conference event in Miami hosted by the Phacilitate event group that brings together thought leaders in cell and gene therapy development for education, collaboration, and networking opportunities, where he shared insights into the intricacies of advanced therapy manufacturing, drawing from his extensive experience in the field, having built and led one of the earliest CDMOs in the marketplace for cell and gene therapies.

AmplifyBio, a leading service provider for the commercialization of advanced modality therapeutics, and Vector BioMed, a biomanufacturing company specializing in the manufacture of lentiviral vectors, announced a strategic partnership that aims to accelerate the development of lentiviral vector-based gene therapeutics.

Adds technology platforms and capabilities in single-cell analysis and product assessment in the context of a tumor microenvironment.